INTRODUCTION {#SEC1}
============

Ribosome profiling via high-throughput sequencing (ribo-seq, ([@B1])) is a promising new experimental technique for identifying the position of ribosomes on messenger RNA (mRNA). Several ribosome profiling protocols have been developed. For example, Aeschimann *et al*. ([@B2]) lyse cells, digest the lysate with RNAseI and purify the monosomes via sucrose gradient fractionation or gel filtration. RNA is then isolated from the monosome fraction, subjected to gel purification and size selection to enrich for mRNA fragments of interest, so-called *ribosome footprints*. The ribosome footprints are then amplified, sequenced and mapped to a genome. We call the pattern of mapped reads for a particular region (e.g. an open reading frame (ORF)) as the region\'s *ribosome profile*, or just *profile*.

Ideally, the ribosome profile reveals exactly and only the position of ribosomes. In practice, though, a variety of other signals and noise ([@B1]), such as RNAs protected by complexes other than the ribosome, amplification biases and sequencing errors, dilute the ribosome profile signal. Furthermore, some evidence suggests that the ribosome can bind to mRNA (and protect it) without actively translating ([@B3]).

The ribosome has known behavior which can help distinguish noise from true signal in ribosome profiles ([@B1]). In particular, the ribosome respects the genetic code and moves along its RNA template during protein synthesis in steps of 3-nt (i.e. size of a codon). Thus, the true signal of an actively translated mRNA transcript should exhibit a periodic 'high-low-low' behavior in which every third base pair has more ribosome footprints than the surrounding base pairs. (While other patterns, such as 'high-low-high,' are also periodic, we specifically refer to the 'high-low-low' pattern with respect to a specific starting point as *periodic*.)

Related work {#SEC1-1}
------------

A variety of techniques have been proposed for analyzing ribo-seq data. Many focus on *translational efficiency* ([@B4]); for example, regression models ([@B5],[@B6]) have been used to detect differences in ribo-seq expression which is not explained by matching [RNA]{.smallcaps}-seq measurements.

Ribosome profiling has also been used to study translational dynamics. For example, Gritsenko *et al*. ([@B7]) estimated translation initiation and elongation rates with ribo-seq. In particular, classic assumptions of tRNA concentrations and elongation rates have been called into question as a result of analysis with ribo-seq data ([@B8]). However, further analysis ([@B9],[@B10]) suggests that variations in protocols significantly affect these estimates.

Recent work ([@B11],[@B12]) has shown that using unannotated ORFs supported by ribo-seq improves downstream proteomics analysis.

The ribosome release score ([@B3]), which is a normalized ratio of reads within an ORF and its transcript trailer, is an early approach for distinguishing translated and untranslated ORFs. The ORFscore ([@B13]) for classifying ORFs is based on the amount by which in-frame reads exceed those in other reading frames; conceptually, ORFscore is quite similar to a χ^2^ test.

[ORF-RATER]{.smallcaps} ([@B14]) extracts characteristics from annotated protein-coding transcripts to train a random forest classifier; the classifier is then used to label unannotated ORFs. It uses linear regression to account for overlapping ORFs. Recently, a hidden Markov model-based approach, [riboHMM]{.smallcaps} ([@B15]), was proposed to handle the variance inherent in ribo-seq profiles; however, [riboHMM]{.smallcaps} requires *ad hoc* approaches to identify more than one translated ORF for each transcript. Both [ORF-RATER]{.smallcaps} and [riboHMM]{.smallcaps} are *supervised* prediction approaches; that is, they require example ORFs *a priori* labeled as 'translated' for training. Thus, these approaches are implicitly biased toward identifying new ORFs similar to the ones selected for training.

A recent *unsupervised* approach, [RiboTaper]{.smallcaps} ([@B16]), uses multitapers to identify ORFs which exhibit 3-nt periodicity. [RiboTaper]{.smallcaps} is the current state of the art and falls into the same domain as [Rp-Bp]{.smallcaps}. That is why, we include a comparison with [RiboTaper]{.smallcaps} in the 'Results' section.

As we discuss in more detail in 'Materials and Methods' section, our approach automatically determines periodic read lengths and P-site offsets. The recent RiboProfiling ([@B17]) package also does this; however, [Rp-Bp]{.smallcaps} uses a principled model selection approach to identify only periodic read lengths and their offsets. Furthermore, [Rp-Bp]{.smallcaps} allows *distinct* P-site offsets for each read length.

Contribution {#SEC1-2}
------------

In this work, we propose an unsupervised Bayesian approach, called *Ribosome profiling with Bayesian predictions*, [Rp-Bp]{.smallcaps}, which takes advantage of the ribosome\'s periodic behavior to identify translated ORFs based on ribosome profiles. That is, we look for a 'high-low-low' pattern in the profiles. By design, [Rp-Bp]{.smallcaps} naturally identifies all translated ORFs which exhibit this pattern, regardless of how many fall on the same transcript.

Conceptually, we capture the periodic behavior using a two-component mixture model. The first component models in-frame ribo-seq signal, which is expected to be high for actively translating ribosomes. The other component enforces periodicity by ensuring that the out-of-frame signal is lower.

The prediction pipeline consists of two phases. It first constructs a profile for each ORF from ribo-seq reads. This phase uses a number of filters to ensure high quality of the profile. We propose a novel probabilistic approach for automatically selecting periodic ribo-seq read lengths and their P-site offsets. Our results show that this automated technique results in modestly more canonical and non-canonical predicted ORFs than manual selection by an expert; the numbers of variants and out-of-frame predicted ORFs remain similar. Importantly, this selection does not require manual intervention, so it is easily integrated into analysis pipelines.

The second phase entails the prediction of ORF translation from the profiles using a different variant of the two-component mixture model. A Bayesian model selection approach is again used to explicitly incorporate and propagate uncertainty in the inference process. Our experimental analysis verifies the accuracy of these predictions using proteomics and an alternative sequencing approach for identifying translation quantitative translation initiation sequencing ([QTI]{.smallcaps}-seq, ([@B18])). Our results also show that [Rp-Bp]{.smallcaps} results in more peptide identifications and ORFs with proteomics validation than [RiboTaper]{.smallcaps}.

MATERIALS AND METHODS {#SEC2}
=====================

Our Bayesian approach for translation prediction, called *Ribosome profiling with Bayesian predictions*, [Rp-Bp]{.smallcaps}, consists of two phases: ORF profile construction (Figure [1](#F1){ref-type="fig"}) and translation prediction (Figure [2](#F2){ref-type="fig"}).

![(**A**) Metagene profiles from a [HEK293]{.smallcaps} dataset for reads with length 20 bp (top) and 21 bp (bottom). The reads of length 21 bp show a clear 3-nt periodicity, while those of length 20 bp do not. (**B**) Simplified view of graphical models for estimating the periodicity of metagene profiles. (Top) The periodic model, H_p, is a two-component mixture model in which the count of the first nucleotide of each codon is drawn from a 'high' component *h* while the other two nucleotides' counts in the codon are drawn from a 'low' component *l*. That is, this model fits the 'high-low-low' pattern of translating ribosomes. (Bottom) The non-periodic model, H_n, is a naïve Bayes model in which all nucleotide counts are drawn from the same distribution.](gkw1350fig1){#F1}
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The ribo-seq ORF profiles are, by design, non-negative integers because they are based on counts. Nevertheless, we model these values with unbounded continuous distributions (Gaussian and Cauchy) in all of the graphical models which follow. As discussed below, we use a smoothing strategy which converts the counts into continuous values. Thus, count-based distributions, such as the negative binomial, are not appropriate in this context. Furthermore, this allows our models to directly use normalized replicates, although we do not pursue that further in this work.

ORF profile construction {#SEC2-1}
------------------------

Our ORF profile construction technique largely follows standard ribo-seq pre-processing protocols (e.g. ref. ([@B2])). A notable difference, discussed below, is our use of probabilistic models to determine read lengths with periodic behavior and their P-site offsets. We also incorporate a simple technique for handling replicates, after correcting for sample-specific biases.

We first construct a *base genome profile*, as follows. (More details, including program and parameter details are in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.) Remove adapters and low quality readsRemove reads mapping to ribosomal sequencesAlign reads to the genome with a splice-aware alignerRemove reads with multiple alignmentsRetain only the 5΄ ends of the unfiltered reads

### Selecting periodic ribo-seq read lengths and P-site offsets {#SEC2-1-1}

The base genome profile contains reads of all lengths present in the dataset (after removing adapters). We next construct a *metagene profile* for each read length by counting the 5΄ read ends aligned at each position in a window around the annotated translation start sites (TSSs). Some read lengths (Figure [1A](#F1){ref-type="fig"}) lead to metagene profiles with clear 'high-low-low' periodicity; for other read lengths (Figure [1A](#F1){ref-type="fig"}), sequencing artifacts dampen, or even completely eliminate, the periodicity. Furthermore, Figure [1A](#F1){ref-type="fig"} is representative in the sense that a 'peak' of ribo-seq reads tends to appear upstream of the annotated TSS. This happens because translation actually occurs at the P-site of the ribosome, not the 5΄ end of the ribosome-protected fragments.

For further processing, we must account for these sequencing and biological artifacts. Previous work typically either used almost all of the read lengths and selected a uniform P-site offset ([@B18]) or selected both manually ([@B16]).

In this work, we use probabilistic graphical models to estimate the periodicity of the metagene profiles of each read length starting at the observed peak. We only keep read lengths which are periodic, according to the models. Furthermore, the location of the peak gives the P-site offset for reads of that length. Thus, we automatically select both the periodic read lengths and their offsets (which may vary for different read lengths within the same dataset due to, for example, sequencing bias). We refer to this technique as *Bayesian Periodic fragment length and P-site offset Selection* (BPPS).

### Constructing the metagene profile {#SEC2-1-2}

We construct the metagene profiles for each read length ℓ by counting the number of 5΄ read ends of length ℓ at each base from 50 bp upstream to 20 bp downstream of all annotated TSSs. The entire metagene profile for ℓ is $\documentclass[12pt]{minimal}
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### Periodic metagene profile model {#SEC2-1-3}

Intuitively, the metagene profile periodicity model, $\documentclass[12pt]{minimal}
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}{}$\mathcal {H}_p$\end{document}$ shown in Figure [1B](#F1){ref-type="fig"}, is a two-component mixture model. The first 'high' (*h*) component models every third nucleotide; due to the known periodic behavior of translating ribosomes, we expect to observe many reads aligned to these locations. The other 'low' (*l*) component models the other two nucleotides of the codon triplets. We additionally model the peak expected at the beginning of the signal. Hard constraints ensure μ~*h*~ \> μ~*l*~, so the model interpretation remains consistent. The periodic observation model for a metagene profile *Y* is as follows: $$\documentclass[12pt]{minimal}
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}{}\begin{eqnarray*} y_{i} &\sim \left\lbrace \begin{array}{lr}\text{Cauchy}(\max (Y), \sigma )) & \text{if } i = 1 \\ \text{Cauchy}(\mu _h, \sigma ) & \text{if } i \ne 1 \text{ and } i \bmod 3 = 1\\ \mathcal {N}(\mu _l, \sigma ) & \text{otherwise,} \end{array} \right. \end{eqnarray*}\end{document}$$ where the notation is as before. The model hyperparameters (which govern priors over μ~*l*~, μ~*h*~ and σ) are set according to empirical estimates. The complete model is in the [Supplementary Data](#sup1){ref-type="supplementary-material"}. The beginning of the metagene profile, *y*~1~, is defined as the peak of the observed counts. The P-site offset for reads of length ℓ is given by the shift necessary such that *y*~1~ coincides with the TSS.

### Non-periodic metagene profile model {#SEC2-1-4}

We use two types of non-periodic models. The first, shown in Figure [1B](#F1){ref-type="fig"}, handles cases in which reads are distributed uniformly throughout the metagene profile. It is a Gaussian naïve Bayes model $$\documentclass[12pt]{minimal}
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The second type of non-periodic model is similar to the periodic model given by Equation [1](#M1){ref-type="disp-formula"}; however, the '$\documentclass[12pt]{minimal}
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In total, then, we have three different non-periodic models. For a particular metagene profile, we select the non-periodic model which best fits that profile and refer to it as $\documentclass[12pt]{minimal}
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### Bayesian model selection {#SEC2-1-5}

Given two competing models for describing a dataset, the Bayes factor ([@B19]) quantifies the extent to which one model should be preferred over the other. Given a metagene profile *Y*, $\documentclass[12pt]{minimal}
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### Bayesian inference {#SEC2-1-6}

We adopt a fully Bayesian approach to calculating the Bayes factor. This allows us to propagate the uncertainty in inference encountered throughout the analysis. Rather than approximating the marginal likelihoods with point estimates, we integrate over the model parameters, as follows: $$\documentclass[12pt]{minimal}
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In general, the integrals in Equation [3](#M3){ref-type="disp-formula"} are intractable. We use the state-of-the-art Hamiltoniam Markov chain Monte Carlo (MCMC) sampler Stan (<http://mc-stan.org/>) to approximate them. Stan uses the No-U Turn Sampler (NUTS) ([@B20]) to effectively tune the MCMC parameters. Long runs of the sampler are guaranteed to converge to the true distribution ([@B21]).

In practice, We selected 200 iterations of MCMC as a reasonable tradeoff between computational cost and convergence. The first 100 iterations are treated as burn-in and discarded; we fit a normal distribution for the likelihood of each model based on the final 100 iterations and approximate *P*(*Y*\| · ) by the mean and variance of this distribution.

After estimating the Bayes' factor for metagene profile *Y*, we select $\documentclass[12pt]{minimal}
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We construct the *filtered genome profile* from the base genome profile in two steps. First, reads of lengths for which $\documentclass[12pt]{minimal}
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### ORF extraction and profile construction {#SEC2-1-7}

We extract ORFs based on transcript exon structures. They could come from standard annotations or *de novo* transcript assembly from [RNA]{.smallcaps}-seq, or both. In particular, we first extract the spliced transcript sequences of all isoforms. We then define an ORF as a start codon until the next in-frame stop codon. (In this work, we consider AUG as the only start codon; the software allows the user to specify other sequences as start codons.) This definition allows multiple start codons to use the same stop codon, but each start codon will only match a single stop codon. Finally, we extract the profile of the ORF by splicing the relevant portions of the filtered genome profile. Thus, the profile *Y* for ORF *o* can be considered as $\documentclass[12pt]{minimal}
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### Combining replicates {#SEC2-1-8}

We use a simple approach to incorporate replicates in [Rp-Bp]{.smallcaps}. In particular, we create the ORF profiles as described above for each replicate. We then construct the combined ORF profile by summing the profiles from all replicates: $\documentclass[12pt]{minimal}
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While this approach is conceptually simple, it has several important properties. First, it allows selection of different read lengths from different replicates. Furthermore, P-sites offsets for reads of the same length can differ between replicates.

### Filtering unlikely ORFs {#SEC2-1-9}

The primary assumption underpinning our approach is that the profiles of translated ORFs exhibit a clear 'high-low-low' pattern. Based on this, we incorporate two simple filters for the ORF profiles. The profile under consideration must have at least five mapped ribo-seq reads.The number of reads mapped to the first reading frame must exceed the number mapped in either of the other two reading frames, individually.

This filtering brings two benefits. First, it saves computations by not considering ORFs which are very unlikely to be translated. Second, as described in more detail later, the second filter simplifies our models and makes the resulting MCMC simulations easier.

### Smoothing profiles {#SEC2-1-10}

The profiles based only on ribo-seq counts tend to be very spiky and sparse. Therefore, we smooth the profiles before proceeding to the translation prediction phase. We use LOWESS ([@B22]); however, we smooth the counts from each frame separately. That is, we construct sequences *Y*^*o*,\ 1^, *Y*^*o*,\ 2^ and *Y*^*o*,\ 3^, where $\documentclass[12pt]{minimal}
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Translation prediction {#SEC2-2}
----------------------

The goal of this work is to identify ORFs which are translated based on the (smoothed) ribo-seq profiles. We accomplish this goal by proposing a mixture model-based *translation model*, $\documentclass[12pt]{minimal}
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### Translation model {#SEC2-2-1}

The ORF translation model is conceptually similar to the metagene profile periodicity model $\documentclass[12pt]{minimal}
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}{}$\mathcal {H}_t$\end{document}$ is essentially a mixture model which comprises one state for in-frame positions and a second for the other two frames. It also looks for 'high-low-low' patterns in profiles. A 'high' state *h* accounts for the in-frame observations, while a 'low' state*l*models observations from the other frames. For an observed ORF profile *Y*, the observation model is as follows: $$\documentclass[12pt]{minimal}
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As previously described, we filter all ORFs for which the number of reads in the second or third reading frames exceed that of the first reading frame. Thus, we do not constrain the mean values of the model components, μ~*h*~ and μ~*l*~. Because of this filtering, they remain semantically correct.

### Background model {#SEC2-2-2}

We use a Gaussian naïve Bayes model to recognize untranslated ORFs. It uses Equation [2](#M2){ref-type="disp-formula"} as its observation model. We refer to the model as $\documentclass[12pt]{minimal}
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### Bayesian model selection and inference {#SEC2-2-3}
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}{}$\mathcal {H}_u$\end{document}$. Again, we explicitly incorporate the uncertainty in inference while making predictions. The experimental results confirm that this methodology leads to high-quality predictions.

### Final prediction set {#SEC2-2-4}

As described above, multiple ORFs may use the same stop codon. For downstream analysis, we select the longest ORF predicted as translated for each stop codon. Finally, among each group of overlapping ORFs, we select the one with the highest expected Bayes factor.

We label the selected ORFs according to their position and exon structure. We use the following labels: [canonical]{.smallcaps}, [can. variant]{.smallcaps} (canonical variants, such as truncations), [uORF]{.smallcaps} (upstream ORFs), [dORF]{.smallcaps} (downstream ORFs), [ncRNA]{.smallcaps} and [other]{.smallcaps}. Additionally, we have [novel]{.smallcaps} ORFs which come only from a *de novo* assembly for *Caenorhabditis elegans*. The [Supplementary Data](#sup1){ref-type="supplementary-material"} precisely defines these labels.

RESULTS {#SEC3}
=======

In this section, we evaluate [Rp-Bp]{.smallcaps} on several ribo-seq datasets using both standard annotations and *de novo* transcript assemblies, described shortly. First, we examine the basic characteristics of the predictions, like the types of ORFs. Experiments demonstrate that the Bayesian length selection technique leads to more canonical and fewer out-of-frame predicted ORFs; we then confirm that the predictions are of high quality with proteomics data and a complementary sequencing technique, [QTI]{.smallcaps}-seq. This validation also includes comparison to [RiboTaper]{.smallcaps} ([@B16]), another recently-proposed approach for identifying translation from ribo-seq data.

Throughout our analysis, we distinguish between *micropeptides* and longer ORFs. We call any ORF with length \<300 nt as a micropeptide. Micropeptides have been repeatedly discussed as potent functional entities in the literature (e.g. ref. ([@B25])).

Our analysis includes datasets from human, mouse and *C. elegans*. Furthermore, the human datasets come from cell cultures, the mouse datasets are tissue-specific and the *C. elegans* datasets are whole-body. Additionally, we analyze the human and mouse datasets in isolation; the *C. elegans* datasets include replicates. Thus, we demonstrate that [Rp-Bp]{.smallcaps} is widely applicable to diverse species and biological experimental designs.

Datasets {#SEC3-1}
--------

In this analysis, we use ten ribo-seq datasets (Table [1](#tbl1){ref-type="table"}): two HEK293 samples and two mouse samples from previous publications, and six unpublished samples from *C. elegans*. Sample preparation and sequencing protocols for the *C. elegans* samples are given in the [Supplementary Data](#sup1){ref-type="supplementary-material"}. As Table [2](#tbl2){ref-type="table"} shows, the quality of the datasets varies substantially. For example, the protocol used to create [HEK293]{.smallcaps} included an rRNA depletion step, so it includes very few reads which map to ribosomal sequences. On the other hand, for example, pre-processing leaves only about 1 000 000 reads for analysis of the [M. Liver]{.smallcaps} and *C. elegans* datasets.

###### The names, abbreviations, original publications and Short Read Archive run accessions of the datasets used in this analysis

  Dataset                          Abbreviation               Source        SRR accession
  -------------------------------- -------------------------- ------------- ---------------
  Human HEK293 cells               [HEK293]{.smallcaps}       ([@B16])      SRR2433794
  Human HEK293 cells               [HEK293-Gao]{.smallcaps}   ([@B18])      SRR1630831
  Mouse liver cells                [M. Liver]{.smallcaps}     ([@B18])      SRR1630812
  Mouse endoplasmic fibroblasts    [M. EF]{.smallcaps}        ([@B18])      SRR1630816
  *C. elegans*, Dauer 0 h          0 h                        unpublished   SRR5026356
  *C. elegans*, Dauer-exit 0.5 h   0.5 h                      unpublished   SRR5026359
  *C. elegans*, Dauer-exit 1 h     1 h                        unpublished   SRR5026589
  *C. elegans*, Dauer-exit 2 h     2 h                        unpublished   SRR5026592
  *C. elegans*, Dauer-exit 3 h     3 h                        unpublished   SRR5026603
  *C. elegans*, Dauer-exit 4 h     4 h                        unpublished   SRR5026637
  *C. elegans* (aggregate)         *C. elegans*               unpublished   

###### The number and percent of reads filtered at each stage of pre-processing for all datasets used in this section

                 M. Liver       M. EF          HEK293         HEK293, Gao    *C. elegans* (aggregate)
  -------------- -------------- -------------- -------------- -------------- --------------------------
  Raw data       9E + 6         3E + 7         3E + 7         3E + 7         9E + 8
  Poor quality   8E + 4 (1%)    4E + 5 (1%)    5E + 5 (2%)    3E + 5 (1%)    4E + 7 (4%)
  Ribosomal      5E + 6 (55%)   6E + 6 (17%)   2E + 6 (7%)    2E + 7 (66%)   5E + 8 (56%)
  No alignment   1E + 6 (15%)   9E + 6 (27%)   3E + 6 (11%)   3E + 6 (10%)   2E + 8 (25%)
  Multimappers   6E + 5 (7%)    8E + 6 (23%)   6E + 6 (20%)   2E + 6 (9%)    3E + 7 (3%)
  Non-periodic   1E + 5 (1%)    4E + 5 (1%)    4E + 5 (2%)    1E + 5 (0%)    6E + 7 (7%)
  Usable         1E + 6 (21%)   1E + 7 (31%)   1E + 7 (59%)   4E + 6 (14%)   4E + 7 (5%)

'Raw data' gives the total number of reads in the dataset. 'Poor quality' reads are either too short after removing adapters or do not have adequate fastq quality scores. 'Ribosomal' reads map to known ribosomal sequences. 'No alignment' reads do not align to the genome. 'Multimappers' map to the genome in multiple locations. 'Non-periodic' reads are of lengths whose metagene profiles do not result in a periodic signal. 'Usable' reads are kept for further analysis. The detailed counts for all samples, including all *C. elegans* replicates, are given in [Supplementary File 7](#sup1){ref-type="supplementary-material"}. We obtain a much higher percentage of rRNA reads from dauer stage lysates than from lysates of other developmental stages of the *C. elegans* life cycle ([@B2]).

We did not treat any of the HEK293 or mouse datasets as replicates. Therefore, the replicate-combining technique in the 'Materials and Methods' section was not used in their analysis.

The six *C. elegans* ribo-seq libraries capture the first 4 h of the dauer exit program in *C. elegans*. We maximize our detection sensitivity by using them as replicates in translation detection as described in the 'Materials and Methods' section.

We use the [hg19]{.smallcaps} genome reference, [GENCODE]{.smallcaps} version 19 annotations and NCBI reference sequence `NR_046235.1` as the ribosomal sequence for the human data. For the mouse data, we use the [GRCm38]{.smallcaps} genome reference and [EnsEMBL]{.smallcaps} 79 annotations; the ribosomal sequence for mouse is [GenBank]{.smallcaps} sequence `BK000964.3`.

For our *C. elegans* analysis, we use the [WBcel235]{.smallcaps} genome reference and corresponding [EnsEMBL]{.smallcaps} 79 annotations. Furthermore, we augment transcript models by assembling newly generated m[RNA]{.smallcaps}-seq datasets, which were generated from dauer larvae at the onset of dauer exit and after 8 h of dauer exit. The *de novo* assembly is available in [Supplementary File 1](#sup1){ref-type="supplementary-material"}.

We merge the [WBcel235]{.smallcaps} annotations with those from our reference-guided *de novo* assembly. We label any ORF which falls entirely on a transcript from the *de novo* assembly as [novel]{.smallcaps}. We use [GenBank]{.smallcaps} sequence `X03680.1` to filter for *C. elegans* ribosomal sequences.

All information on the final predicted ORFs for all datasets are available as [Supplementary Files 2--6](#sup1){ref-type="supplementary-material"}.

Predicted ORF characteristics {#SEC3-2}
-----------------------------

### Translated ORF types {#SEC3-2-1}

Table [3](#tbl3){ref-type="table"} shows that the proportions of ORF types predicted by [Rp-Bp]{.smallcaps} for the human and mouse datasets are similar. Around 75% of the predicted ORFs are [canonical]{.smallcaps}, annotated coding regions or variants, while about 20% of the translated ORFs come from annotated 5΄ leaders or non-coding regions; the remaining translated ORFs are located in either annotated 3΄ trailers or are out-of-frame with respect to the annotated coding regions. These results are consistent with other ribosome profiling studies ([@B14],[@B16]).

###### The number of ORFs of each type predicted by [Rp-Bp]{.smallcaps}

                               *C. elegans*   HEK293         HEK293, Gao   M. EF        M. Liver
  ---------------------------- -------------- -------------- ------------- ------------ ------------
  [canonical]{.smallcaps}      11 558 (82%)   11 056 (64%)   8237 (60%)    9471 (59%)   549 (65%)
  [can. variant]{.smallcaps}   1918 (14%)     1097 (6%)      2129 (16%)    1187 (7%)    1918 (22%)
  [uORF]{.smallcaps}           71 (1%)        2244 (13%)     1216 (9%)     1858 (12%)   456 (5%)
  [dORF]{.smallcaps}           35 (0%)        383 (2%)       425 (3%)      1719 (11%)   45 (1%)
  [ncRNA]{.smallcaps}          254 (2%)       2 201 (13%)    1115 (8%)     1355 (8%)    154 (2%)
  [other]{.smallcaps}          154 (1%)       217 (1%)       554 (4%)      490 (3%)     453 (5%)
  [novel]{.smallcaps}          41 (0%)                                                  

The ORF types are described in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.

We see a different story for *C. elegans*, though. Almost all of the [Rp-Bp]{.smallcaps} ORFs are [canonical]{.smallcaps} or canonical variants. Indeed, there are very few [uORF]{.smallcaps}s or [dORF]{.smallcaps}s predicted as translated. We attribute these differences to the fundamental different genome organization and annotation quality of *C. elegans*.

In the [Supplementary Data](#sup1){ref-type="supplementary-material"}, we show the metagene profiles of the translated ORF types. As previously observed ([@B14]), a spike is present in reads mapping to both the start and stop codons for all ORF types for almost all samples; the [M. Liver]{.smallcaps} and *C. elegans* datasets do not exhibit a spike at the stop codons, though. These results confirm that [Rp-Bp]{.smallcaps} identifies ORFs with the hallmarks of translation.

### UniRef comparison {#SEC3-2-2}

As a final validation of the basic characteristics of the predicted ORFs, we compared their lengths to the lengths of proteins in the [UniRef90]{.smallcaps} database ([@B26]). We also included ORF predicted as translated by [RiboTaper]{.smallcaps}. [Supplementary Figure S3](#sup1){ref-type="supplementary-material"} shows that the lengths of [Rp-Bp]{.smallcaps} ORFs match those in [UniRef90]{.smallcaps} much better than those predicted by [RiboTaper]{.smallcaps}. In general, [UniRef90]{.smallcaps} includes more short ORFs (not including micropeptides, ORFs with length \<300 bp) than identified by either method; however, the number of longer [Rp-Bp]{.smallcaps} ORFs is similar to the number present in [UniRef90]{.smallcaps}, while [RiboTaper]{.smallcaps} predicts many more longer ORFs.

The length distribution of the [Rp-Bp]{.smallcaps} ORFs for *C. elegans* closely follows that of *C. elegans*[UniRef90]{.smallcaps}. Since so many of the predicted ORFs are [canonical]{.smallcaps}, this is unsurprising.

Bayesian periodic fragment length and P-site offset selection (BPPS) {#SEC3-3}
--------------------------------------------------------------------

The BPPS technique has several goals. First, the approach aims to automatically select periodic read lengths in an unbiased manner, while still avoiding noisy read lengths. Second, the approach identifies non-standard (12 bp) P-site offsets. Very recent findings highlight the importance of both aspects ([@B27]). This helps to improve sensitivity in translation predictions by using more of the available reads.

To verify the efficacy of this approach, we compared the [Rp-Bp]{.smallcaps} ORFs found using BPPS to using standard length selection approaches. In particular, for the [HEK293]{.smallcaps} dataset, we compared BPPS with using lengths 26, 28 and 29 bp and P-site offsets 9, 12 and 12 bp, respectively; for [HEK293-Gao]{.smallcaps}, we compare to lengths 26, 27, 28 and 29 bp and P-site offsets of 12 bp for all lengths. These lengths and offsets were manually selected and used in previous analysis ([@B16]).

Similarly, previous analysis ([@B18]) of [M. EF]{.smallcaps} and [M. Liver]{.smallcaps} used all reads of lengths 25--35 and P-site offsets of 12 bp for all read lengths; we compare our Bayesian length selection approach to those values. In the [Supplementary Data](#sup1){ref-type="supplementary-material"}, we examine the differences among the *C. elegans* replicates.

### Differences in BPPS and manual selections {#SEC3-3-1}

First, Figure [3](#F3){ref-type="fig"} confirms that BPPS identifies many more periodic read lengths than the restricted manual selection for [HEK293]{.smallcaps} and [HEK293-Gao]{.smallcaps}. The main disagreement between the automatic selection and manual curation is the P-site offset for reads of length 26 bp in [HEK293]{.smallcaps}; however, using an offset of either 9 or 12 bp does not result in a change of frame for those reads. BPPS does remove some non-periodic read lengths from downstream analysis, such as reads of length 20 bp for [HEK293]{.smallcaps}. Additionally, the automatic approach does identify non-standard P-site offsets, such as 13 bp for [HEK293]{.smallcaps} reads of length 31 and 3 bp for [HEK293-Gao]{.smallcaps} reads of length 19 bp.

![The selected read lengths and P-site offsets selected by BPPS compared to manual selection.](gkw1350fig3){#F3}

On the other hand, when compared to the very broad selections originally made for [M. EF]{.smallcaps} and [M. Liver]{.smallcaps}, our approach does not include the longer reads. Instead, we select many of the smaller read lengths, sometimes with non-standard offsets. This highlights that manual selection may ignore useful reads while including noisy ones.

In the [Supplementary Data](#sup1){ref-type="supplementary-material"}, we further examine the differences among predictions with [BPPS]{.smallcaps} and manual selection based on whether the ORFs had external validation, such as proteomics. We again find no significant differences.

### Differences in ORF predictions {#SEC3-3-2}

We then compared the [Rp-Bp]{.smallcaps} ORFs using either BPPS or manually-selected read lengths and P-site offsets. As shown in Figure [4](#F4){ref-type="fig"}, the different selection techniques result in modest, but distinctly different, patterns among the [Rp-Bp]{.smallcaps} ORFs. In particular, in both [HEK293]{.smallcaps} and [M. EF]{.smallcaps}, BPPS results in more [canonical]{.smallcaps}, [uORF]{.smallcaps}, [dORF]{.smallcaps} and [ncRNA]{.smallcaps} ORFs, while manual selection results in more [can. variant]{.smallcaps} features. Both techniques result in a similar number of out-of-frame overlapping ORFs. This shows that the predictions using BPPS are of higher quality than those from manual selection. Of course, BPPS also has the advantage that it automatically adapts to choose the best lengths and offsets rather than requiring manual selection.

![The number of [Rp-Bp]{.smallcaps} ORFs using BPPS and manual length and P-site offset selection for the human and mouse datasets. The ORF types are described in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.](gkw1350fig4){#F4}

Proteomics analysis {#SEC3-4}
-------------------

We next used two high-quality mass spectrometry proteomics datasets (PRIDE accessions \[PXD002389 and PXD001468\] and MaxQuant ([@B28]--[@B30])) to compare the proteomics-verified support of predicted ORFs for [HEK293]{.smallcaps}. We compare the ORFs predicted by [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} as well as those annotated as protein coding in [GENCODE]{.smallcaps}. We also generated a *C. elegans* mass spectrometry proteomics dataset to verify the predictions made by [Rp-Bp]{.smallcaps}; the `WBcel235` annotations are used as a baseline for comparison. The details of the proteomics analysis are in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.

### *In silico* digestion {#SEC3-4-1}

As a baseline, we first compared the theoretical number of peptide sequences each set of ORFs could possibly identify; we found these via *in silico* digestion of the respective peptide sequences. (More details are presented as part of the [Supplementary Data](#sup1){ref-type="supplementary-material"}.) Figure [5](#F5){ref-type="fig"} shows that [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} result in a similar number of peptides, while, [GENCODE]{.smallcaps} includes many more possible peptides. This is expected since the [GENCODE]{.smallcaps} annotations are not cell type-specific. According to the theoretical digestion, both [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} identify tens of thousands of peptides distinct from each other and [GENCODE]{.smallcaps}. The differences from [GENCODE]{.smallcaps} arise from [ncRNA]{.smallcaps} and other non-canonical ORFs.

![The number of peptide sequences identified with (**A**) *in silico* digestion of the annotated proteins from [GENCODE]{.smallcaps}, and the ORFs predicted by [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} for [HEK293]{.smallcaps}, (**B**) *in silico* digestion of the annotated proteins from [WBcel235]{.smallcaps} and [Rp-Bp]{.smallcaps} for *Caenorhabditis elegans*, (**C** and **D**) MaxQuant for the respective datasets. The *in silico* digestion and MaxQuant details are given in the [Supplementary Data](#sup1){ref-type="supplementary-material"}.](gkw1350fig5){#F5}

The relative overlap among the [Rp-Bp]{.smallcaps} ORFs for *C. elegans* and the annotations is somewhat higher. As mentioned, though, many of the *C. elegans*[Rp-Bp]{.smallcaps} ORFs are [canonical]{.smallcaps}, so it is expected that the predicted ORFs have more in common with the annotated proteins.

### MaxQuant detection {#SEC3-4-2}

We then compared the number of peptide sequences actually detected using MaxQuant for each set of ORFs. While the overlap among the three sets of ORFs from [HEK293]{.smallcaps} shown in Figure [5](#F5){ref-type="fig"} is quite high, [Rp-Bp]{.smallcaps} results in several thousand uniquely-identified peptides compared to either [RiboTaper]{.smallcaps} or [GENCODE]{.smallcaps}. In contrast, [RiboTaper]{.smallcaps} and [GENCODE]{.smallcaps} only produce about a thousand unique ORFs each. The *in silico* peptide analysis showed that [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} yield a similar number of possible peptides, so [Rp-Bp]{.smallcaps} does not result in more unique peptides than [RiboTaper]{.smallcaps} simply because more are possible. Besides the peptides unique to [Rp-Bp]{.smallcaps}, another reason more peptides are detected using [Rp-Bp]{.smallcaps} ORFs is that it produces a smaller number of sequences than [RiboTaper]{.smallcaps} and [GENCODE]{.smallcaps}; consequently, the false discovery rate and error probabilities calculated by MaxQuant are lower. Similarly, more *C. elegans* peptides are detected using the [Rp-Bp]{.smallcaps} ORFs than annotations.

### Peptide support for [Rp-Bp]{.smallcaps} ORF types {#SEC3-4-3}

We next analyzed the peptide support for all ORFs predicted as translated by [Rp-Bp]{.smallcaps}. Over 75% of the [canonical]{.smallcaps}[Rp-Bp]{.smallcaps} ORFs have peptide support (Figure [6](#F6){ref-type="fig"}), and a majority of the canonical variants also have peptide support. Additionally, over 20% of the ORFs annotated as [ncRNA]{.smallcaps} or [dORF]{.smallcaps}, but predicted as translated, have peptide support. While the peptide support for [uORF]{.smallcaps}s is not as strong, in total, the proteomics analysis validates the accuracy of many of the predictions made by [Rp-Bp]{.smallcaps} for longer ORFs.

![The percentage of each type of [Rp-Bp]{.smallcaps} ORF (≥300 nt) from the [HEK293]{.smallcaps} and *Caenorhabditis elegans* datasets with proteomics support. An ORF is considered to have proteomics support if at least one peptide detected by MaxQuant exactly aligns to the translated protein sequence for the ORF. Furthermore, we require the peptide uniquely align to that ORF. The numbers on the bars show the number of ORFs with and without proteomics support, as indicated.](gkw1350fig6){#F6}

For *C. elegans*, about half of the [canonical]{.smallcaps} ORFs, and a third of their variants, were supported by the proteomics data. However, the other ORF types do not have as much proteomics support. Nevertheless, as shown in Table [3](#tbl3){ref-type="table"}, about 95% of the [Rp-Bp]{.smallcaps} ORFs *are*[canonical]{.smallcaps} or variants. So many of the predictions do in fact have peptide support.

### Comparison of [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} peptide support {#SEC3-4-4}

We also evaluated the peptide support of the predicted ORFs in [HEK293]{.smallcaps} as a function of the length of the ORFs, shown in Figure [7](#F7){ref-type="fig"}. We included the ORFs predicted by [RiboTaper]{.smallcaps} in this evaluation. For this analysis, we again use only peptides which uniquely map to an ORF. We first considered the support of the micropeptides (ORF length \<100aa). As Figure [7A](#F7){ref-type="fig"} and [B](#F7){ref-type="fig"} shows, micropeptides do not have much support from the proteomics data. It is technically challenging to obtain peptide evidence from these very short proteins during the proteomics experiments and thus expected that few of these have peptide support. Still, in terms of raw numbers and percentage of predictions, more [Rp-Bp]{.smallcaps} micropeptides have unique proteomics support than those from [RiboTaper]{.smallcaps}. The [Rp-Bp]{.smallcaps} results for *C. elegans* are similar to those for [HEK293]{.smallcaps}.

![(**A** and **B**) The percentage of [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} micropeptides of different lengths (\<100aa) with proteomics support in [HEK293]{.smallcaps}. Proteomics support is described in the caption of Figure [6](#F6){ref-type="fig"}. All ORF types are grouped based on bin sizes of 20 bp. The numbers on the bars show the number of micropeptides with and without proteomics support, as indicated. (**C** and **D**) The percentage of all [Rp-Bp]{.smallcaps} and [RiboTaper]{.smallcaps} ORFs with unique proteomics support in [HEK293]{.smallcaps}. All ORF types are grouped based on bin sizes of 300 bp. The counts are also available in [Supplementary File 8](#sup1){ref-type="supplementary-material"}.](gkw1350fig7){#F7}

We then considered unique peptide support for longer ORFs in Figure [7C](#F7){ref-type="fig"} and [D](#F7){ref-type="fig"}. Herein, the percentage of ORFs at almost all read lengths with unique peptide support is much higher for [Rp-Bp]{.smallcaps} on [HEK293]{.smallcaps} compared to [RiboTaper]{.smallcaps}. As with the micropeptides, in terms of raw counts, [Rp-Bp]{.smallcaps} results in modestly more ORFs with unique peptide support; as discussed previously, [RiboTaper]{.smallcaps} predicts many more longer ORFs are translated than [Rp-Bp]{.smallcaps}. These results show that many of the longer ORFs do not have unique peptide support.

### *C. elegans* micropeptides {#SEC3-4-5}

The percentage of [Rp-Bp]{.smallcaps}*C. elegans* ORFs predictions, shown in Figure [8B](#F8){ref-type="fig"}, with unique peptide support is somewhat less than that for the human data; however, proteomics replicates were available for human, so it is unsurprising that more ORFs had proteomics validation. Nevertheless, the percentage of [Rp-Bp]{.smallcaps}*C. elegans* micropeptides with proteomics validation, in Figure [8A](#F8){ref-type="fig"}, is somewhat higher than for the [HEK293]{.smallcaps} dataset, especially for micropeptides between 150 and 300 nt.

![The percentage of [Rp-Bp]{.smallcaps} *Caenorhabditis elegans* (**A**) micropeptides and (**B**) all ORFs with unique proteomics support, as described in Figure [7](#F7){ref-type="fig"}. The counts are also available in [Supplementary Table S8](#sup1){ref-type="supplementary-material"}.](gkw1350fig8){#F8}

Finally, we identified 3622 novel transcripts in *C. elegans* with a reference-guided transcriptome assembly approach (see [Supplementary File 1](#sup1){ref-type="supplementary-material"}). Several of them harbor small ORFs that could encode for [novel]{.smallcaps} micropeptides in *C. elegans*. We predicted 41 [novel]{.smallcaps} ORFs as being translated, 37 of which are micropeptides (\<300 bp). We found unique proteomics support for one of the micropeptides. In essence, [Rp-Bp]{.smallcaps} is able to identify novel coding regions even in genomes, which are excessively curated such as *C. elegans*.

Taken together, these results show that [Rp-Bp]{.smallcaps} predictions from different species are well-supported by proteomics data. The predictions result in more unique peptide identifications from proteomics data compared to standard annotations and [RiboTaper]{.smallcaps} predictions; a large majority of the longer ORFs have peptide support, and even many of the predicted micropeptides have support from the proteomics data.

[QTI]{.smallcaps}-seq analysis {#SEC3-5}
------------------------------

[QTI]{.smallcaps}-seq ([@B18]) is a recently-developed protocol for identifying ribosomes initiating translation. Briefly the method consists of lysing cells, freezing initiating ribosomes with lactimidomycin and depleting elongating ribosomes with puromycin. Thus, only initiating ribosomes remain and, after further detailed protocols, the associated cDNA can be sequenced.

Matching [QTI]{.smallcaps}-seq datasets are available ([@B18]) for all human and mouse ribo-seq datasets used in this study. We matched reported [QTI]{.smallcaps}-seq peaks to the start codon of all annotated transcripts and compared this to the set of transcripts with [Rp-Bp]{.smallcaps} ORFs. The ORFs identified by [Rp-Bp]{.smallcaps} show very good agreement with [QTI]{.smallcaps}-seq peaks; as Figure [9](#F9){ref-type="fig"} shows the *P*-values of the overlaps for all datasets are very close to 0. This gives another form of validation that the predictions by [Rp-Bp]{.smallcaps} accurately reflect the biology in the cell.

![The overlap of transcripts with a [QTI]{.smallcaps}-seq peak within 50 bp of the annotated start codon and a [Rp-Bp]{.smallcaps} ORF (of any type). The *P*-values are calculated using a hypergeometric test.](gkw1350fig9){#F9}

DISCUSSION {#SEC4}
==========

The ribosome profiling protocols offer a genome-wide view of the activity of the ribosome. However due to biological and technical artifacts, principled analysis techniques are required to fully leverage the ribo-seq profiles. We proposed a fully Bayesian translation prediction approach, [Rp-Bp]{.smallcaps}. The heart of [Rp-Bp]{.smallcaps} lies in state-of-the-art MCMC sampling via Stan (`http://mc-stan.org/`) to estimate posterior distributions from biologically-inspired models of (un)translation. Bayesian model selection is then used to estimate a posterior distribution of translation. Unlike previous work ([@B23],[@B24]), we do not resort to point estimates, but instead maintain distributions over quantities of interest through the entire process. Thus, our pipeline propagates uncertainty to improve later predictions.

Additionally, we use the Bayesian model selection technique in a novel approach for selecting periodic ribo-seq read lengths appropriate for downstream analysis; it also automatically determines the P-site offset for each read length.

On publicly-available ribo-seq datasets, we show that the Bayesian read length selection approach results in more canonical and non-canonical ORFs predicted as translated. Furthermore, validation with high-quality proteomics and QTI-seq data confirm the predictions are of very high quality. Our proteomics analysis also demonstrates that more [Rp-Bp]{.smallcaps} ORFs have unique peptide alignments compared with [RiboTaper]{.smallcaps} ([@B16]), another recent translation-prediction pipeline. Additionally, [Rp-Bp]{.smallcaps} results in more peptide identifications than [RiboTaper]{.smallcaps}.

As suggested in the method description, one limitation of [Rp-Bp]{.smallcaps} is its unnormalized parameter estimates. For example, it would not be appropriate to compare estimates from two different datasets. A natural next step is normalization of the ribo-seq profiles so the parameter estimates are useful for differential translation analysis. Another venue for further development are more sophisticated models that could aid in distinguishing isoforms, detecting overlapping ORFs and identifying programed frameshifts.

AVAILABILITY {#SEC5}
============

Our implementation of [Rp-Bp]{.smallcaps} is available at `https://github.com/dieterich-lab/rp-bp`. The pipeline is implemented as a set of Python3 scripts and is installed via `pip`. A simple driver script runs the entire pipeline; it can optionally submit the processing to the Simple Linux Utility for Resource Management (Slurm) workload manager. The software requires a genome reference fasta file and matching GTF3/GFF annotations. The final output is a valid BED12 file with the predicted ORFs, as well as DNA and protein fasta files containing the predicted sequences.

Supplementary Material
======================
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Click here for additional data file.
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